Indication
Chronic Phase
15 clinical trials
18 products
Clinical trial
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-03-03
Product
RadotinibProduct
ImatinibProduct
PonatinibClinical trial
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesStatus: Active (not recruiting), Estimated PCD: 2020-04-14
Clinical trial
A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
HS-10382Clinical trial
A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With Chronic Myeloid Leukemia.Status: Recruiting, Estimated PCD: 2024-12-30
Product
HQP1351Product
TERN-701Clinical trial
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including ImatinibStatus: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission (ALERT CML)Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Acetylsalicylic acidProduct
AsciminibProduct
Ascimininb + NilotinibProduct
Asciminib + ImatinibProduct
Asciminib + DasatinibClinical trial
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia in Combination With Asciminib and Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
Collection of Biological Resources During Medical Care of Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase for an Epigenetic Study of Leukemic Stem CellsStatus: Recruiting, Estimated PCD: 2025-05-01
Product
Blood and Bone MarrowClinical trial
Phase 2 Clinical Trial With Ponatinib as a Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Prior First Line Tyrosine Kinase Inhibitor TreatmentStatus: Terminated, Estimated PCD: 2023-02-28
Clinical trial
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
olverembatinibProduct
BosutinibClinical trial
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2025-01-01
Product
RuxolitinibClinical trial
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular RemissionStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Product
DasatinibProduct
NilotinibClinical trial
Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLStatus: Not yet recruiting, Estimated PCD: 2028-09-01